ES was equally effective in newly diagnosed MM and RRMM patient samples, with an LD50 value of 38.22 nM (Figure 5F, range 9.3–83.4 nM), suggesting that HDAC11 remains a vulnerability in both early- and late-stage MM. This evidence concerns the gene HDAC11 and Miyoshi myopathy.